Heparin-induced thrombocytopenia: a rare presentation with skin necrosis


0
0
0
0
Smart Citations
0
0
0
0
Citing PublicationsSupportingMentioningContrasting
View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Authors

  • Filipa David Internal Medicine Service, Medical Department, Hospital Pedro Hispano, Matosinhos, Portugal.
  • Ana Catarina Trigo Internal Medicine Service, Medical Department, Hospital Pedro Hispano, Matosinhos, Portugal.
  • José Ribeiro Internal Medicine Service, Medical Department, Hospital Pedro Hispano, Matosinhos, Portugal.
  • Joana Cancela Internal Medicine Service, Medical Department, Hospital Pedro Hispano, Matosinhos, Portugal.

Heparin-induced thrombocytopenia is the most clinically relevant non-hemorrhagic complication of heparin and is characterized by the presence of anti-platelet factor 4 (PF4)/heparinimmunoglobulin G (IgG) antibodies. The circulating PF4/heparin- IgG immune complex binds to platelets via their FcyIIa receptors, activating them and promoting their aggregation, with consequent platelet consumption, thrombocytopenia, and thrombotic phenomena. Despite thrombocytopenia, this condition is not typically associated with bleeding complications. Instead, thrombosis is the most serious complication of heparin-induced thrombocytopenia, contributing to increased morbidity and mortality. Thrombotic events can be venous and arterial, such as deep vein thrombosis, pulmonary embolism, myocardial infarction, and thrombotic stroke. Skin necrosis at the site of heparin injections is a rare but well-described manifestation of heparin-induced thrombocytopenia. We report a case of heparin-induced thrombocytopenia presented as skin necrosis, highlighting the importance of recognizing this potentially fatal condition and the need for an immediate cessation of all sources of heparin and its replacement by other anticoagulants.